Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MAINTENA KIT vs ANEXSIA 7.5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Treatment of schizophrenia,Maintenance monotherapy for bipolar I disorder,Adjunctive treatment of major depressive disorder (off-label),Irritability associated with autistic disorder (off-label),Tourette's disorder (off-label)
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing.
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole.
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites).
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein.
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution.
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%.
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
No adjustment for mild/moderate impairment; caution in severe impairment (Cr Cl <30 m L/min).
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
Not approved for pediatric use.
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects.
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
Hypersensitivity to aripiprazole or any excipients in the formulation.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
Aripiprazole is excreted in human breast milk; the estimated infant dose is 0.7–1.4% of maternal weight-adjusted dose. M/P ratio: approximately 0.3–0.5. Limited data suggest no adverse effects in breastfed infants, but long-term safety is unknown.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
No specific dose adjustment recommended based on pharmacokinetic changes; however, therapeutic drug monitoring may be considered due to altered metabolism in pregnancy. The long-acting injectable formulation (Abilify Maintena) requires careful timing of doses postpartum to avoid relapse.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
This medication is given as an injection every 4 weeks by a healthcare professional.,Do not stop taking your oral aripiprazole until your doctor tells you to.,Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat.,Avoid alcohol and driving until you know how this medicine affects you.,Report any uncontrolled movements of the face, tongue, or other body parts to your doctor.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MAINTENA KIT vs ANEXSIA 7.5/325, answered by our medical review team.
ABILIFY MAINTENA KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.. ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MAINTENA KIT and ANEXSIA 7.5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MAINTENA KIT is: 400 mg IM once monthly after establishing tolerability with oral aripiprazole.. The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MAINTENA KIT and ANEXSIA 7.5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MAINTENA KIT is classified as Category C. First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, includin. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.